ABSTRACT
Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment option for malignant hematological disorders. Transplant clinicians estimate patient-specific prognosis empirically in clinical practice based on previous studies on similar patients. However, this approach does not provide objective data. The present study primarily aimed to develop a tool capable of providing accurate personalized prognosis prediction after allo-HCT in an objective manner.
Methods We developed an interactive web application tool with a graphical user interface capable of plotting the personalized survival and cumulative incidence prediction curves after allo-HCT adjusted by eight patient-specific factors, which are known as prognostic predictors, and assessed their predictive performances. A random survival forest model using the data of patients who underwent allo-HCT at our institution was applied to develop this application.
Results We succeeded in showing the personalized prognosis prediction curves of 1-year overall survival (OS), progression-free survival (PFS), relapse/progression, and non-relapse mortality (NRM) interactively using our web application (https://predicted-os-after-transplantation.shinyapps.io/RSF_model/). To assess its predictive performance, the entire cohort (363 cases) was split into a training cohort (70%) to develop the predictive model and test cohort (30%) to confirm its performance time-sequentially. The areas under the receiver-operating characteristic curves for 1-year OS, PFS, relapse/progression, and NRM in test cohort were 0.70, 0.72, 0.73, and 0.77, respectively.
Conclusions The new web application could allow transplant clinicians to inform a new allo-HCT candidate of the objective personalized prognosis prediction and facilitate decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant (number 17K09017).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure: The authors declare no conflicts of interest.
Funding: This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant (number 17K09017).
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to the ethically sensitive nature of the research. Although they may be provided by the corresponding author on reasonable request, its request must be submitted to the Research Ethics Committee in our hospital and be approved.
ABBEREVIATIONS
- ADTree
- alternating decision tree
- allo-HCT
- allogeneic hematopoietic cell transplantation
- AUC
- area under the receiver-operating characteristic curve
- CB
- cord blood
- CI
- confidence interval
- Cox PH
- Cox proportional hazard
- DRI-R
- refined disease risk index
- EBMT
- European Group for Blood and Marrow Transplantation
- GITMO
- Italian Group for Bone Marrow Transplantation
- GUI
- graphical user interface
- haplo-PB
- haploidentical peripheral blood
- HCT-CI
- hematopoietic cell transplantation comorbidity index
- HLA
- human leukocyte antigen
- MAC
- myeloablative conditioning
- NRM
- non-relapse mortality
- OS
- overall survival
- PFS
- progression-free survival
- PS
- performance status
- rBM
- related bone marrow
- RIC
- reduced intensity conditioning
- rPB
- related peripheral blood
- RSF
- random survival forest
- uBM
- unrelated bone marrow